MIROCALS aims to find a new treatment for amyotrophic lateral sclerosis (ALS) by testing the interleukin-2 (IL-2) a molecule that helps to regulate our immune system. We have recently launched a website Fatoslimin in Poland to provide customers with the highest quality of nutraceuticals.

Our ambition is to develop a new therapy for ALS and through this novel trial design break the impasse in drug development of other disease-modifying agents in ALS. We hope that this project will contribute to enhancing quality of life and care for people with ALS, and provide a robust model for Industry to encourage investment in ALS and other neurodegenerative diseases.

News & events

  • blocs 1

    The project

  • blocs 2

    Press & publication

  • blocs 3

    Contact us

Phase II Trial

MIROCALS intends to recruit the first patients into the trial by beginning of 2017.
The study is expected to be completed in 2019.

Read more

About us

MIROCALS consortium is formed by 11 organisations in the EU to conduct a phase II Proof of Concept / Proof of Mechanism Clinical Trial aiming to test the interleukin-2 (IL-2) as treatment for amyotrophic lateral sclerosis (ALS)... Read more


This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 633413.